Imlifidase met its primary endpoint in a 50-patient European post-authorisation study, supporting SERB's planned full marketing authorisation application to the EMA.

Hansa Biopharma has revealed positive results from the Idefirix PAES study presented at ASN Kidney Week 2026, demonstrating excellent outcomes for kidney transplant patients.

Hansa Biopharma revealed promising data for Idefirix during ASN Kidney Week 2026, showcasing impressive survival rates for kidney transplant patients.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Hansa Biopharma (HNSA) announced a partnership with Cradle to use its AI-driven protein engineering platform across Hansa's drug discovery pipeline. Hansa will use the platform to design, optimize and advance therapeutic candidates for severe autoimmune diseases. The platform combines candidate generation with optimization and learning from experimental data.Hansa's lead product, imlifidase, is commercially available in Europe as Idefirix. It is under FDA review for highly sensitized patients awaiting kidney transplant, with a December PDUFA date, the target date for an FDA review decision.

Imlifidase is an antibody-cleaving enzyme originating from Streptococcus pyogenes that specifically targets and cleaves immunoglobulin G (IgG) antibodies and inhibits IgG-mediated immune response

Hansa has announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix.

Hansa Biopharma has achieved a significant milestone in Australia with the first commercial kidney transplant using Idefirix, enhancing patient options in transplantation.

Hansa Biopharma has successfully treated its first kidney transplant patient in Australia with Idefirix, marking a significant advancement in transplant procedures.

Hansa Biopharma has achieved a significant milestone with the first successful commercial living donor kidney transplant in Australia, treated with Idefirix. This advancement marks a new chapter for kidney transplant patients.

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication...

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication...

SERB Pharmaceuticals will acquire imlifidase's European and MENA commercialisation rights from Hansa Biopharma, targeting highly sensitised kidney transplant patients.

Study shows Hansa's Idefirix helps deliver Genethon's AAV8 gene therapy GNT003 in previously ineligible Crigler-Najjar patient by clearing antibodies, reports Do Cao at ESGCT.

Sarepta and Hansa formed the partnership in 2020 to determine if Idefirix could broaden the patient population for Elevidys.

Study shows Hansa's Idefirix helps deliver Genethon's AAV8 gene therapy GNT003 in previously ineligible Crigler-Najjar patient by clearing antibodies, reports Do Cao at ESGCT.

Hansa Biosciences will discuss next steps for Idefirix in DMD with Sarepta Biosciences.

BRUSSELS, July 01, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company designed to address rare and urgent conditions, today announced that it has completed the acquisition of exclusive development and commercialization rights to Idefirix® (imlifidase) in the...

Hansa Biopharma said on Tuesday it had agreed to license its kidney transplant drug Idefirix to privately held SERB Pharmaceuticals ​in Europe and some other markets for up to ‌115 million euros ($134 million), bolstering the Swedish biotech firm's balance sheet as it prepares for a potential U.S. launch of the drug later this ​year.

Hansa Biopharma and SERB Pharmaceuticals have finalized a €115 million agreement for Idefirix, enhancing access in Europe and MENA. This milestone promises to address critical patient needs in kidney transplantation.